Clinical Trial Details

A Study of NX-1607 in Adults With Advanced Malignancies

Complete Title: A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types
Trial Phase: I
Investigator: John Liao

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

Keywords:
  • Urothelial Cancer; Gastroesophageal Junction Cancer; Richter Syndrome; Ovarian Cancer; Lung Carcinoma, Non-Small-Cell (NSCLC); Prostate Cancer, Castration-resistant (CRPC); Colorectal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Triple Negative Breast Neoplasms; Gastric Cancer; Head and Neck Cancer; Melanoma; Mesothelioma
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Checklist icon

Join a Clinical Trial

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Contact Us

If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.